Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate

• DOI: 10.1097/fpc.0b013e3283398a71
• Publication Date: 2010-04-13T04:52:01Z
• Authors: Lisa K. Stamp; Peter T. Chapman; John L. O'Donnell; Mei Zhang; Jill James; Christopher Frampton; Murray L. Barclay; Martin A. Kennedy; Rebecca L. Roberts
• Keywords: Glycine Hydroxymethyltransferase; 0301 basic medicine; Erythrocytes; Polymorphism, Genetic; Multidrug Resistance-Associated Protein 2; AMP Deaminase; 3. Good health; Arthritis, Rheumatoid; Ferredoxin-NADP Reductase; 03 medical and health sciences; Folic Acid; Methotrexate; Polyglutamic Acid; Humans; Longitudinal Studies; Methylenetetrahydrofolate Reductase (NADPH2); Genome-Wide Association Study

To determine whether genetic polymorphisms within the folate pathway are associated with red blood cell (RBC) methotrexate (MTX) polyglutamate concentrations, RBC folate concentrations and MTX efficacy/toxicity.Disease activity in 200 rheumatoid arthritis patients on MTX was assessed by swollen and tender joint counts and Disease Activity Score 28. Genetic polymorphisms shown to have an effect on gene expression or protein function were examined.RBC folate concentrations were significantly associated with MTHFR 677C>T (P=0.002), MTRR 66A>G (P<0.0001), MTHFD1 1958G>A (P=0.001) and SHMT 1420C>T (P=0.012), whereas no association of these polymorphisms with disease activity was observed. None of the polymorphisms tested predicted RBC MTX polyglutamate concentrations. There were weak associations between central nervous system adverse effects and AMPD1 34C>T (P=0.04) and between gastrointestinal adverse effects and MTHFD1 1958G>A (P=0.03) and ABCC2 IVS23+56T>C (P=0.045). There was a stronger association between any adverse effect and ABCG2 914C>A (P=0.004).Although RBC folate concentrations are associated with genetic polymorphisms within the folate pathway, these variants do not predict disease activity. To accurately evaluate whether any polymorphisms are reliable predictors of MTX efficacy or toxicity, large prospective clinical trials are required. Furthermore, application of a genome-wide association strategy is likely to uncover novel predictors of MTX response.